PureTech Health News
Press Releases
Press releases 2018-01-03
Selective mTORC1 Inhibitors
PureTech Health Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice President, to Board of Directors

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that resTORbio, an affiliate of PureTech Health, today announced that Lynne Sullivan, Senior Vice President of Finance for Biogen, Inc., has joined the resTORbio board of directors as an independent director.

Continue
Press releases 2018-01-02
Selective mTORC1 Inhibitors
PureTech Health Affiliate resTORbio Files Public Registration Statement for Proposed Initial Public Offering

PureTech Health plc (LSE: PRTC) announced that resTORbio, Inc., an affiliate of PureTech Health, has filed a public registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock.

Continue
Press releases 2017-12-19
Oral Administration of Biologics – Novel Hydrogel
PureTech’s Entrega To Receive $5 Million Investment from Lilly To Advance Proprietary Oral Delivery Technology for Peptides

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Entrega, an affiliate of PureTech Health, today announced a research collaboration with Eli Lilly and Company (NYSE: LLY) (“Lilly”).

Continue
Press releases 2017-12-13
Microbiome-Derived Immune Modulators
PureTech’s Vedanta Biosciences Granted Four New US Patents Expanding Coverage for Compositions and Methods of Use for Medicines Based on Microbiome-Derived Bacterial Consortia

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, today announced that the United States Patent and Trademark Office (USPTO) has issued four new patents to Vedanta Biosciences, which broadly cover compositions of matter and methods of use for therapeutic products, including mixtures of bacterial strains and spore-forming fractions based on beneficial bacteria.

Continue
Press releases 2017-12-11
Selective mTORC1 Inhibitors
PureTech Health Affiliate resTORbio Adds Paul Fonteyne, CEO of Boehringer Ingelheim USA, to Board of Directors

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that resTORbio, an affiliate of PureTech Health, today announced that Paul Fonteyne, President and CEO of Boehringer Ingelheim USA, has joined the resTORbio board of directors as an independent director.

Continue
Press releases 2017-12-07
Microbiome-Derived Immune Modulators
PureTech’s Microbiome Programme Advances into a Phase 1a/1b Clinical Trial

VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has received Orphan Drug Designation from the US FDA for C. difficile indication

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, today announced the initiation of a Phase 1a/1b clinical trial of VE303, the Company’s lead, orally-administered, human microbiome-derived product candidate.

Continue
Press releases 2017-12-05
Selective mTORC1 Inhibitors
PureTech’s resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
Continue
Press releases 2017-12-04
Cognitive Interference Processing
PureTech’s Akili Achieves Primary Endpoint in Pivotal Study of Investigational Digital Medicine for Paediatric ADHD

This successful outcome builds on recent clinical achievements and value created at PureTech Health

PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Akili Interactive Labs, Inc., an affiliate of PureTech Health, today announced positive results from its pivotal study in paediatric attention-deficit/hyperactivity disorder (ADHD).

Continue
Press releases 2017-11-30
Selective mTORC1 Inhibitors
PureTech’s resTORbio Raises $40 Million from Leading Biotech and Institutional Investors

This financing brings the total capital raised by this affiliate in 2017 to $65 million which will be used to advance its novel immunotherapy for aging-related conditions

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, announced today that resTORbio, Inc. (resTORbio), an affiliate of PureTech Health, completed an oversubscribed $40 million equity round led by OrbiMed and including participation from Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio.

Continue
Press releases 2017-11-29
Microbiome-Derived Immune Modulators
PureTech’s Vedanta Biosciences Expands Clinical Translational Collaborations in Cancer Immunotherapy

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, has expanded its international network of clinical, translational medicine collaborations.

Continue

@PureTechH

Exploring the Brain Immune Gut Interface

Targeting serious diseases caused by dysfunctions in the brain-immune-gut axis

See Our Science